Cite
HARVARD Citation
Tuffy, K. et al. (n.d.). 1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies. Open forum infectious diseases. p. . [Online].